Yong-Soo Bae | Immunology Cellular Interactions | Best Researcher Award

Published on by Cell Biologist

Prof. Dr. Yong-Soo Bae | Immunology Cellular Interactions | Best Researcher Award

Prof. Dr. Yong-Soo Bae | Sungkyunkwan University | South Korea

Dr. Yong-Soo Bae is a distinguished immunologist and professor at the Department of Biological Science, Sungkyunkwan University, Korea. He currently serves as the Director of the SRC Center for Immune Research on Non-lymphoid Organs (CIRNOS). With over three decades of academic, clinical, and industry experience, Dr. Bae is internationally recognized for his pioneering research in immunology, virology, and vaccine development. His multidisciplinary contributions span academia, biotech innovation (as CEO/CTO of JW Creagene Inc.), and scientific leadership, including organizing global conferences and serving as editor-in-chief and president in numerous societies. His work focuses on immune modulation, cancer immunotherapy, and mucosal vaccines, which has led to influential publications in prestigious journals like Nature Communications, Science Advances, and Advanced Materials. Dr. Bae’s career reflects a commitment to innovation, collaboration, and education, making him a strong candidate for the Best Researcher Award.

Publication Profile:

Scopus

✅ Strengths for the Award

  1. Pioneering Research Leadership
    Dr. Bae has led groundbreaking research in immunology, particularly in immune regulation of non-lymphoid organs, vaccine development, and cancer immunotherapy. His leadership of the Center for Immune Research on Non-lymphoid Organs (CIRNOS) demonstrates his national influence in immune research.

  2. Extensive Scientific Contributions
    With over 18 high-impact publications in the past 3–4 years alone, including in top-tier journals like Nature Communications, Molecular Therapy, Science Advances, and Advanced Materials, Dr. Bae continues to push the boundaries of translational immunology and personalized medicine.

  3. International & Interdisciplinary Experience
    His training at Harvard Medical School, his professorships across Korean institutions, and leadership at JW Creagene Inc. showcase both academic and industrial impact.

  4. Scientific Community Engagement
    Roles such as Editor-in-Chief, society president, and organizer of global conferences (e.g., DC2012) reflect his commitment to advancing scientific dialogue and collaboration.

  5. Mentorship and Institutional Development
    Dr. Bae has contributed significantly to capacity building in Korea’s biomedical research landscape, mentoring junior scientists and shaping departmental growth.

⚠️ Areas for Improvement:

  1. Global Collaboration Visibility
    While his work is highly impactful in Korea and Asia, more joint publications with global institutions (e.g., NIH, Oxford, Karolinska) could further enhance international research influence.

  2. Patent and Commercial Output Reporting
    As former CEO/CTO of JW Creagene, elaborating on patented innovations or therapeutic products brought to market would strengthen the case for translational impact.

  3. Formal Recognition or Awards
    Inclusion of formal honors (e.g., national science medals, international society awards) would help quantify his recognition outside Korea.

  4. Consistent Author Disambiguation
    In some publications, author names appear as “Y.S. Bae” or “Yong-soo Bae.” Consistent use of a standardized author name across indexing platforms would help centralize his citation metrics and scholarly footprint.

 

🎓 Education:

Dr. Yong-Soo Bae’s academic journey began with a Bachelor’s and Master’s degree in Microbiology from Seoul National University in 1981 and 1983, respectively. His foundational training in microbiology laid the groundwork for his research trajectory in infectious disease and immunology. He earned his Ph.D. in 1990 from the University of Calgary, Alberta, Canada, in the Virology Division of the Department of Microbiology and Infectious Diseases, Faculty of Medicine. His doctoral research was crucial in shaping his interest in host-pathogen interactions and immune regulation. Dr. Bae’s international education experience has enabled him to blend Western and Eastern biomedical research paradigms, contributing to his ability to lead collaborative global projects and initiatives in immunotherapy and vaccine innovation.

💼 Experience:

Dr. Yong-Soo Bae’s professional career spans academia, research, and biotech leadership. He completed a postdoctoral fellowship at Dana-Farber Cancer Institute, Harvard Medical School (1991–1993), which enriched his expertise in cancer immunology. He held professorial roles at Hannam University (1993–2003) before joining Sungkyunkwan University in 2004, where he later became Department Chair and Distinguished Professor. Dr. Bae also served as Director of CIRNOS (2017–2024) and led JW Creagene Inc. as CEO/CTO (1998–2015), bridging science and industry. His editorial and leadership roles include Editor-in-Chief of the Journal of Bacteriology and Virology, President of the Korean Society of Virology, and Vice President of the Korean Vaccine Society. His diverse roles demonstrate a unique blend of academic excellence, organizational leadership, and translational research expertise.

🔍 Research Focus:

Dr. Yong-Soo Bae’s research focuses on innate and adaptive immune regulation, tumor immunology, mucosal immunotherapy, and vaccine delivery. He investigates cellular interactions in the immune microenvironment, with particular attention to innate lymphoid cells (ILCs), neutrophils, and dendritic cells. His translational work includes novel vaccine platforms, epitranscriptomics, immune checkpoint modulation (e.g., CISH, PD-1), and cell therapy for diseases such as asthma, leukemia, and cancer. He also explores microbiome-immune crosstalk and inflammation-related organ damage (e.g., renal fibrosis, lung inflammation). His group has published extensively on m6A modifiers, microRNAs, and innovative delivery systems like gel-to-nanovaccines. His latest studies dive into immunometabolism and the interplay between immune cells and tissue repair, offering groundbreaking insights for future immunotherapies. Dr. Bae’s work is highly cited and remains at the forefront of immune system-based therapeutic innovation.

📚 Publications Top Notes:

  1. 📘 Therapeutic Potential of microRNA Against Th2-associated Immune Disorders – Current Topics in Medicinal Chemistry (2021)

  2. 💉 COVID-19 Vaccines and Oral-Mucosal Vector System as a Potential Vaccine Platform – Vaccines (2021)

  3. 🧬 Immunotherapeutic Potential of m6A-Modifiers and microRNAs in AML – Biomedicines (2021)

  4. 🎯 Epitranscriptomic Approach to Improve ICB Therapy by Targeting CISH – Cells (2021)

  5. 🧫 TFH-B-TRM Dysregulation and Anti-PD-1 Responses in EGFR-mutant Lung Cancer – Nature Communications (2021)

  6. 🧪 Adenoviral CD200R-Ig Enhances Antitumor Immunity via M2 Macrophage Inhibition – Molecular Therapy

  7. 🌫 Air Pollutant-induced Neutrophils Worsen Airway Inflammation – JACI (2021)

  8. 🦠 NCR+ILC3s and the Microbiome in Asthma Severity – Immune Network (2021)

  9. 📖 Advances in Personalized Therapy for AML by Targeting Intracellular Checkpoints – eBook Chapter (2021)

  10. 🧵 Siglec-F Neutrophils Drive Fibrosis in Renal Disease – JCI (2022)

🧾 Conclusion:

Dr. Yong-Soo Bae is an exceptional and highly deserving candidate for the Best Researcher Award. His contributions over four decades span foundational research, translational innovation, academic leadership, and scientific diplomacy. The depth of his scientific output, particularly in immunology, epigenetics, and vaccine development, is matched by his long-term commitment to mentoring, editorial work, and building research institutions in Korea.While enhancing his global recognition and expanding international collaborative outputs could further elevate his status, Dr. Bae’s consistent high-impact contributions, research leadership, and policy involvement clearly position him as a top-tier researcher in the life sciences.

Yidong Wei | Immunology Cellular Interactions | Best Researcher Award

Published on by Cell Biologist

Prof. Yidong Wei | Immunology Cellular Interactions | Best Researcher Award

Prof. Yidong Wei , Shanghai Tenth People’s Hospital, Tongji University , China

Dr. Yidong Wei, M.D., Ph.D., FACC, is a distinguished professor and the Chief of Cardiology at Shanghai Tenth People’s Hospital, Tongji University. He also holds a clinician management role at the Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford. With a strong foundation in both clinical and translational research, Dr. Wei has built an internationally recognized career focused on interventional cardiology, cardiac electrophysiology, and cardiovascular epidemiology. He is a Fellow of the American College of Cardiology, reflecting his global academic influence. Known for bridging clinical care with bench-side discovery, his work has advanced understanding in myocardial infarction, heart failure, and calcium signaling in cardiomyocytes. With numerous high-impact publications and leadership in multicenter registries like NOAFCAMI-SH, Dr. Wei’s contributions are widely cited and clinically relevant. His dual academic and clinical roles across China and the UK highlight his dedication to innovation, international collaboration, and excellence in cardiovascular medicine.

Publication Profile:

Scopus

✅ Strengths for the Award:

  1. High-Impact Research Output:
    Dr. Wei has authored or co-authored more than 18 recent peer-reviewed publications in prestigious journals such as Diabetes Metabolism Research and Reviews, Redox Biology, Cardiovascular Diabetology, and ESC Heart Failure. Many of these works are already cited, indicating early academic impact and relevance.

  2. Dual Focus – Basic and Clinical Science:
    His research bridges the gap between molecular mechanisms (e.g., calcium signaling, TRIM21, PTEN) and clinical cardiology (e.g., atrial fibrillation, myocardial infarction, cardiac remodeling), highlighting a robust translational focus.

  3. Leadership and Collaboration:
    He serves as Chief of Cardiology at Shanghai Tenth People’s Hospital and a Clinician Manager at the University of Oxford, demonstrating international leadership and cross-border collaboration.

  4. Registry Leadership (NOAFCAMI-SH):
    His work through the NOAFCAMI-SH registry provides real-world evidence on cardiovascular disease progression, risk prediction, and treatment response—critical for patient-centered care.

  5. Prestigious Recognition:
    Dr. Wei is a Fellow of the American College of Cardiology (FACC), a title reserved for top-tier cardiovascular professionals with sustained excellence.

⚠️ Areas for Improvement:

  1. Broader International Research Leadership:
    While Dr. Wei has strong China–UK collaborations, leading global multicenter clinical trials or international consortia would further solidify his standing.

  2. Public Engagement and Knowledge Translation:
    Though academically prolific, increased involvement in public health education or policy advocacy could amplify the real-world impact of his research.

  3. Mentorship Track Record Visibility:
    Highlighting mentorship of junior researchers and postdocs more explicitly in profiles and bios would enhance his case for a holistic academic leadership award.

🎓 Education:

Dr. Wei began his medical education at Henan Medical University, where he completed clinical training with a focus on cardiovascular medicine. Driven by a passion for research, he pursued and completed his Ph.D. in 2004, with a specialization in cardiac electrophysiology and calcium signaling pathways. His graduate studies were complemented by advanced basic science training at the University of Kentucky, USA, a leading institution in biomedical research. Between 2004 and 2006, Dr. Wei completed postdoctoral research, focusing on the molecular mechanisms of cardiac dysfunction and electrophysiology. His educational background reflects a balanced integration of rigorous clinical education and innovative research development, equipping him with the tools necessary to bridge bedside care with laboratory insights. This foundation has allowed Dr. Wei to contribute to both academic medicine and cutting-edge cardiovascular research, distinguishing him as a leader with comprehensive and global training in the field.

🏥 Experience:

With over two decades of experience, Dr. Yidong Wei serves as Professor and Chief of the Department of Cardiology at Shanghai Tenth People’s Hospital, Tongji University. His role extends internationally, acting as Clinician Manager at the University of Oxford’s Centre for Diabetes, Endocrinology and Metabolism. His clinical expertise spans interventional cardiology, acute coronary syndromes, and electrophysiological interventions, while his research roles emphasize trial design, biomarker discovery, and cellular cardiology. He has led and contributed to large-scale registries like NOAFCAMI-SH, generating evidence that informs guidelines for myocardial infarction and atrial fibrillation. His professional experience combines healthcare leadership, cross-border academic collaboration, and impactful research. As a Fellow of the American College of Cardiology, he is actively engaged in academic societies and peer-reviewed journals. Dr. Wei’s experience reflects an enduring commitment to patient care, innovation in research, and mentorship of future cardiology leaders, marking him as a high-impact contributor in his field.

🔬 Research Focus:

Dr. Yidong Wei’s research lies at the intersection of clinical cardiology and molecular medicine. He focuses on interventional cardiology, atrial fibrillation, myocardial infarction, and calcium signaling pathways in cardiac myocytes. A major theme in his work is the electrophysiological basis of heart failure and age-related changes in ventricular function. Using techniques like patch clamping, calcium imaging, laser confocal microscopy, and molecular biology, he investigates calcium channel regulation and excitation-contraction coupling in cardiac cells. Clinically, he leads research through the NOAFCAMI-SH registry, analyzing systemic inflammation, hyperglycemia, atrial fibrillation, and long-term cardiac outcomes. His work advances the understanding of post-infarction remodeling and atrial pathology. Combining basic science with real-world data, Dr. Wei’s research bridges gaps in translational cardiology and offers therapeutic targets for chronic cardiac conditions. His integrative approach makes him a pioneer in translating bench findings into bedside impact, with potential to redefine cardiac care strategies globally.

📚 Publications Top Notes:

  1. 📈 Association of stress hyperglycemia ratio with atrial fibrillation and outcomes in myocardial infarction

  2. 🧪 Prognostic implications of systemic immune-inflammation index in MI patients with and without diabetes

  3. 🧬 TRIM21 deficiency protects heart post-MI by reducing oxidative stress

  4. 🫀 4S-AF scheme for characterizing atrial fibrillation after myocardial infarction

  5. 🔬 TRIM21 worsens cardiac injury via M1 macrophage polarization post-MI

  6. 🧮 Stress hyperglycemia and outcomes in MI with and without diabetes mellitus

  7. 💉 ZPI protects endothelium via PI3K/Akt pathway activation against ox-LDL

  8. 📊 Atrial fibrillation’s prognosis across heart failure subtypes post-MI

  9. 🕒 Five-year outcomes post left atrial appendage occlusion

  10. 🧫 PTEN and serum deprivation-induced cytotoxicity via PI3K/AKT pathway

🧾 Conclusion:

Dr. Yidong Wei stands out as a highly suitable candidate for the Best Researcher Award. His contributions to cardiovascular research—spanning cutting-edge basic science to influential clinical trials—are both innovative and impactful. His leadership roles, international presence, and translational focus align perfectly with the goals of this prestigious recognition. Given his trajectory, Dr. Wei is not only a leader in current cardiovascular research but also a driver of future scientific breakthroughs.